APVO — Aptevo Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671584 ·
Last close
$4.11
Market Cap
$5.12M
52W High
$5.62
52W Low
$3.68
ADV30
70,273
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,837,000 | -6,697,000 | 19,902,000 | 14,524,000 | 8,290,000 |
| Dec 2025 | 0 | — | -5,996,000 | -5,806,000 | 27,194,000 | 21,619,000 | 9,813,000 |
| Sep 2025 | 0 | — | -7,610,000 | -7,549,000 | 26,996,000 | 21,061,000 | 9,604,000 |
| Jun 2025 | 0 | — | -6,226,000 | -6,204,000 | 15,624,000 | 9,410,000 | 9,100,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,982,000
Investing CF
$0
Financing CF
$39,368,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1779.56
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-281,909,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-26,669,000
Pretax Income TTM
$-26,256,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,312,000 | -25,967,000 | 27,194,000 | 9,813,000 | — | -25,592,000 |
| Dec 2024 | 0 | -24,602,000 | -24,130,000 | 15,591,000 | 10,836,000 | — | -23,785,000 |
| Dec 2023 | 0 | -28,878,000 | -17,411,000 | 24,842,000 | 12,621,000 | — | -11,730,000 |
| Dec 2022 | 3,114,000 | -28,641,000 | 8,027,000 | 34,215,000 | 16,241,000 | — | -21,022,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-21.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GLMD | Galmed Pharmaceuticals Ltd. | $5.13M | $0.62 | — |
| HCWB | HCW Biologics Inc. | $5.11M | $3.20 | — |
| INBP | INTEGRATED BIOPHARMA INC | $4.97M | $0.16 | — |
| JAGX | Jaguar Health, Inc. | $4.91M | $1.00 | — |
| RNAZ | Transcode Therapeutics, Inc. | $4.83M | $4.56 | — |
News headlines (Yahoo Finance, 1h cache)
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
2026-07-27 12:05 · Yahoo
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
2026-06-30 12:05 · Yahoo
APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement
2026-06-16 09:15 · Yahoo
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
2026-05-28 12:05 · Yahoo
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
2026-05-27 12:05 · Yahoo
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
2026-05-20 16:00 · Yahoo
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
2026-05-13 12:05 · Yahoo
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 D
2026-05-06 12:05 · Yahoo
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
2026-04-10 16:00 · Yahoo
Aptevo to Participate in March 2026 Conferences
2026-03-19 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.